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ABSTRACT 
 
MULTIPLE CONSERVED ENHANCERS OF THE OSTEOBLAST MASTER 
TRANSCRIPTION FACTOR, RUNX2, INTEGRATE DIVERSE SIGNALING 
PATHWAYS TO DIRECT EXPRESSION TO DEVELOPING BONE 
Christopher William Weber 
Shannon Fisher 
The vertebrate skeleton forms via two distinct modes of ossification, 
membranous and endochondral. Osteoblasts are also heterogeneous in 
embryonic origin; bone formed by either mode can be derived from neural crest 
cells or mesoderm. In contrast, all bone develops via a common genetic pathway 
regulated by the transcription factor Runx2. Runx2 is required for bone 
formation, and haploinsufficiency in humans causes the skeletal syndrome 
cleidocranial dysplasia, demonstrating the importance of gene dosage. Despite 
the central role of Runx2 in directing bone formation, little is understood about 
how its expression is regulated in development. We took an unbiased approach to 
identify direct regulatory inputs into Runx2 transcription by identifying cis–
regulatory elements associated with the human gene. We assayed conserved 
non-coding elements in a 1 Mb interval surrounding the gene for their ability to 
direct osteoblast expression in transgenic zebrafish. We identified three 
enhancers spaced out across the interval. Within each we identified conserved 
transcription factor binding sites required for their activity, and further showed 
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distinct and specific regulation of each. The enhancer in the last intron of 
RUNX2 itself is positively regulated by the FGF signaling pathway, an enhancer 
in the last intron of the adjacent gene, SUPT3H, is regulated by canonical Wnt 
signaling, and a distant downstream enhancer requires a conserved Dlx binding 
site for its activity. While all of these pathways and factors have been previously 
implicated in bone formation, our results provide the first direct links to the 
common genetic pathway regulating osteogenesis, transcription of Runx2. These 
findings further illustrate the integration of multiple regulatory inputs at the 
level of transcription of a key developmental gene, and highlight the role of 
Runx2 as the gatekeeper for changes in skeletal morphology achieved through 
alterations in gene expression. 
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CHAPTER 1 
Characteristics of the vertebrate skeleton 
The presence of a mineralized endoskeleton is one of the common features 
of the vertebrate lineage 1 . In addition to its historically understood roles in 
support and as the sites of muscle attachment, the skeleton has more recently 
been understood to be the site of hematopoiesis 2 , endocrine regulation of glucose 
metabolism 3 , a reservoir for inorganic minerals 4   and critical in male 
reproductive function 5 .    
The vertebrate skeleton is chiefly composed of two tissue types: bone and 
cartilage.a  Cartilage is the more evolutionarily primary of the two 6 .  While not 
possessing a ‘true’ skeleton, the chordate amphioxus expresses orthologs of 
cartilage marker genes in the nascent notochord 7 . Cartilage is composed of 
chondrocytes suspended in a rigid matrix rich in collagen fibrillar proteins and 
acidic polysaccharides 8 . The most abundant of these proteins are type II 
collagen and aggrecan, whose negative charge accounts for the osmotic swelling 
of the tissue 9 , resulting in the familiar rigid plasticity of the material. This 
property confers a biomechanical role in the fully realized skeleton, allowing 
articular surfaces of joints to tolerate compressive forces. 
Conversely, bone is vascularized, has a higher metabolic activity and 
differs in its extracellular matrix (ECM) composition both in the content of 
secreted proteins, but also in the presence of inorganic calcium 10 . Unlike the 
                                                          
a Two other tissue types found exclusively in teeth are dentin and enamel, though 
they will not be discussed further in this document.  
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cartilage ECM, 90% of the total dry protein weight is type I collagen.  Collagen I 
forms an extensively crosslinked fiber, around which calcium crystals in the form 
of spindles of hydroxyapatite are deposited, resulting in the characteristic 
rigidity of bone tissue 11 . Other well-characterized components include alkaline 
phosphatase, osteopontin, and osteocalcin 12 . 
Osteoblasts are the cells responsible for the deposition of this defining 
matrix. Correspondingly, they have a highly basophilic cytoplasm and extensive 
endoplasmic reticulum and Golgi apparatus 13  to produce substantial amounts of 
secreted protein. Following matrix deposition, osteoblasts either become lining 
cells or remain embedded in bone, the latter defined as osteocytes 14 . These cells 
account for 95% of mature bone tissue.  Another bone cell type, osteoclasts, 
arises from the monocytic/macrophage lineage postnatally 15 . These cells have a 
resorbative role in bone homeostasis and therefore regulate bone mass density.  
Embryonic origins of the vertebrate skeleton 
Skeletogenesis describes the process by which mesenchymal stem cells 
(MSCs) differentiate into osteoblasts and chondrocytes in a defined program. 
MSCs are loose, multipotent cells with the capacity to differentiate into non-
skeletal cell types such as adipocytes or myocytes 16 .  Whether commitment to 
the skeletal lineage involves the existence of a bipotential skeletal precursor cell 
type, capable of adopting a bone or cartilage fate, is at issue in the literature 17  .  
Skeletal elements in the embryo forms via two distinct processes. 
Intramembrous ossification describes direct condensation of migrated MSCs and 
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subsequent transformation to bone 18 .  This process is employed in the creation 
of the flat bones of the skull as well as fracture repair. Elsewhere, particularly in 
the long bones, endochondral ossification results in the calcification and invasion 
of a cartilaginous scaffold by osteoprogenitor cells 19 . A complementary 
heterogeneity is observed in the embroynic origin of MSCs, where neural crest, 
lateral plate, and somitic mesoderm all contribute to the developing skeleton 16 .   
Genetic origins of the vertebrate skeleton – Runx2 
However, this diversity contrasts with the uniform genetic origin of 
skeletal tissues. Commitment to the osteoblast lineage requires the expression of 
the early marker gene and runt domain containing transcription factor Runx2 20 .  
The runt domain is a site of protein-protein interaction, as well as binding to the 
core sequence 5’- PyGPyGGTPy-3’ 21 .  Runx2 -/- mice fail to generate any 
osteoblasts 22 , and chondrocyte maturation and terminal differentiation are 
disturbed 23 . Additionally, haploinsufficency at the locus causes the skeletal 
disorder cleidocranial dysplasia, marked by delayed closure of the fontanelles of 
the skull, hypoplasticity of the clavical, and other features 24 (OMIM# 119600). 
RUNX2 binds to and upregulates other osteoblast marker genes 25 , which are 
also upregulated following forced expression of Runx2 in non-skeletal tissues, 
including fibroblasts, C3H10T1/2 cells, primary myoblasts, and marrow stromal 
cells  25-27 .  For these reasons, Runx2 has been recognized as occupying an 
indispensable bottleneck position in the osteoblast fate switch and is often 
referred to the master regulator of osteoblast development 28 . 
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 The dosage of Runx2 must be finely tuned in order to properly execute 
differentiation. Overexpression of Runx2 in osteoblasts arrests bone development 
in a mouse model, resulting in an osteopenic phenotype 29 . Forced expression in 
chondrocytes produces precociously mature cells that produce osteoid tissue and 
bone marrow not present in orthologous structures in wild type animals 30 . 
Despite Runx2’s unquestioned indispensability early in fate commitment, the 
notion that Runx2 might not have a role in mature osteoblasts has been 
proposed, as expression of a dominant negative form of the protein exclusively in 
mature osteoblasts does not affect transcription of the osteoblast marker 
osteocalcin, a gene that can be activated by forced expression of Runx2 in non 
osteoblastic cells 25, 31 . 
Genetic origins of the vertebrate skeleton – sp7/osx 
  An answer to potential regulators of later osteoblast differentiation came 
with the identification of Sp7/Osx as a cDNA species specifically expressed in 
C2C12 cells undergoing osteoblastogenesis. Sp7 codes for a zinc finger-
containing transcription factor from the Kruppel-like factor family 32 .  As with 
Runx2, inactivation of  in mouse models yielded a skeleton devoid of osteoblasts; 
however  mineralization did occur in bones formed by endochondral ossification, 
though the features of those tissues were more akin to a mineralized form of 
cartilage. Interestingly, Runx2 expression levels were unaffected, indicating that 
Sp7 is not upstream of Runx2. Further work located Sp7 as a direct target of  
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Runx2 b. Sp7 is recruited to its own promoter in murine UMR106-01 
osteosarcoma cells to the exclusion of other members of the sp transcription 
factor family in a manner that correlates with the expression of sp7 33 . 
 Sp7 is thought to function exclusively in later osteoblast differentiation 
and distinct from the activities of Runx2 in cartilage. Among Sp7’s target genes 34 
are the bone marker genes Col1a1 35 , Bsp 36  and Ocn. The regulation of Col1a1 
by Sp7 is corroborated clinically by a report of a proband presenting with 
osteogenesis imperfecta and a frameshift mutation within the SP7 coding region 
37 . Finally, in contrast to Runx2, Sp7 function appears to be critical for postnatal 
growth and maintenance of bone 38 .  
Molecular signaling and the vertebrate skeleton – The BMP pathway 
 Bone morphogenetic proteins (BMPs) were initially identified on the basis 
of their ability to induce de novo bone and cartilage formation in vivo 39, 40 . Most 
BMPs are members of the transforming growth factor- superfamily of proteins 
with important roles in both proper patterning and differentiation of the 
skeletonc.  Canonically, signaling starts upon BMP ligand binding to heteromeric 
cell surface receptors composed of BMPR-I and BMPR-II receptors. This 
activated complex phosphorylates cytoplasmic SMAD proteins via a serine-
threonine kinase domain.  SMADs 1,5 and 8 bind to a co-SMAD upon 
phosphorylation and enter the nucleus to directly affect gene transcription via 
                                                          
b Allen, unpublished observation 
c Notably, BMP-1 is a metalloproteinase. 
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chromatin binding. As will be discussed in future sections, the Smad proteins 
offer a context for crosstalk with other signaling pathways. 
 Understanding the role of BMP signaling in skeletogenesis is complicated 
by the presence of multiple components with distinct, yet overlapping, activities, 
as well the necessity of BMP signaling in early embryo patterning formation. 
BMP-2, --4,-6,and -7 are ligands with demonstrable osteogenic potential in vitro, 
yet genetic studies using conditional knockout alleles reveal more subtle and 
complementary roles. Both Bmp2 and Bmp4 activities are dispensable for the 
formation of the long bones, of the limbs, though deletion of the former results in 
an increase of fractures postnatally 41, 42 .  Similarly, loss of Bmpr2 43  and Bmp7 
have no demonstrable effect on bone formation or fracture repair in the limbs 44 .  
However, a double knockout of Bmp2 and Bmp4 results in a severe impairment 
of osteogenesis, indicating a redundancy in these roles 45 .  
 Runx2 upregulation has been observed in in vitro systems following BMP 
stimulation 46, 47 , and consequently, Runx2 is thought to be the principle mediator 
of downstream BMP actions 48 . However, there are also thought to be BMP 
signals capable of driving osteoblastogenesis independently of Runx2. Although 
BMP-2 administration is not capable of driving full differentiation of osteoblasts 
and chondroblasts in Runx2-deficient mouse calvarial cell lines, upregulation of 
alkaine phosphatase, osteocalcin and sp7 is detectable  22, 49, 50 . BMP-2 treatment 
upregulates sp7 expression in C2C12 cells independently of Runx2 51 .  Also, 
preosteoblastic cell lines require autocrine BMP signaling for proper 
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differentiation, although they already express Runx2 52, 53 . Finally, activated 
SMAD proteins interact physically and functionally with RUNX2, suggesting a 
synergistic relationship to complement the Runx2 dependent and independent 
BMP signaliing axes. SMAD1 and RUNX2  transcription factors complex to drive 
gene expression on target gene promoters 54 . An osteoblast specific deletion of 
Smad1 causes an osteopenic phenotype 55 , and combined deletion of Smad1/5/8 
results in severe chondrodysplasia 56 .  
 Pretreatment with the ribosome inhibitor cyclohexamide prior to BMP-2 
treatment blocks the induction of Runx2 57  and sp7 58 , indicating the need for the 
synthesis of an intermediate protein to complete the signaling axis. Among the 
direct targets of BMP signaling with known roles in skeletogenesis are 
homeodomain proteins. In particular, microarray experiments examining the 
transcriptional response to BMP-2 treatment in cultured C2C12 osteoprogenitor 
cells have identified members of the meshless(Msx), distalless(Dlx), and 
aristaless(Alx) transcription factor families as being immediately and transiently 
induced, prior to the commitment to osteogenesis evidenced by expression of 
Runx2 59-61 . Mutations associated with the Msx1 and Msx2 loci demonstrate 
consequences in skeletal patterning and differentiation. Msx1-/- mice exhibit 
craniofacial and tooth development abnormalities including a cleft palate 
phenotype 62 , while Msx2-/- mice possess delayed calvarial bone growth, defects 
in endochondrial ossification and chondrogenesis, as well as reduced expression 
of osteocalcin and Runx2  63 . Simultaneous deletion of both Msx2 and Msx1 
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results in the complete absence of craniofacial bone 63, 64  A reversal of this dosage 
effect is evidenced in a human MSX2 gain of function mutant with enhanced 
DNA binding, eliciting a premature fusion of the calvarial sutures and 
craniosynostosis 65 . Significantly, microduplications upstream of MSX2 
containing many conserved non-coding elements phenocopy CCD, suggesting a 
potentially rigid regulatory apparatus between BMP signaling and Runx2 in vivo 
66  . 
In tetrapods, members of the Dlx gene family are grouped in binary 
clusters, facing each other via their 3’ ends as a result of presumptive gene 
duplication events 67 . Dlx1 and Dlx4 have important roles in tooth development 68  
and hematopoiesis 69 , respectively, but they have not been identified as 
expressed in osteoblasts.  Although Dlx3 inactivation results in embryonic 
lethality, it is expressed in osteoblastic lineage cells during endochondral 
ossification, and at its highest level in mature osteocalcin and Runx2 expressing 
osteoblasts 70, 71 . A 4bp frameshift deletion in the human DLX3 gene causes an 
autosomal dominant disease, tricho-dento-osseous syndrome (OMIM#600525), 
which is characterized by altered dermal bone formation in the skull as well as 
increased bone density 72 .  Consistent with this observation, interaction between 
DLX3 and RUNX2 reduces the capacity of RUNX2 to direct transcription at the 
osteocalcin promoter in a cell culture context 73 .  
Current opinion in the literature designates Dlx5 as a critical regulator of 
BMP mediated osteogenesis 74 . Simultaneous knockout of the Dlx5/6 cluster 
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results in gross skeletal abnormalities, including absence of the calvaria, 
maxilliary and mandibular bones, as well as a generalized ossification delay in 
the axial skeleton 75 . These anomalies are also seen in Dlx5 -/- mice; curiously, no 
data on a Dlx6 -/- phenotype has been published. Dlx5 induction by BMPs has 
been observed in both the contexts of cell culture(MC3T3-E1 cells) 76  and in vivo 
development(chick skull development) 77 , where Dlx5 expression is visible in 
proliferating suture mesenchyme not yet committed to an osteoblastic fate, 
suggesting a role in fate designation prior to Runx2 induction. Dlx5 induces 
Runx2 in immature calvaria mesenchyme culture 78 , and Dlx5 and Runx2 have 
been shown to be recruited together at the stimulated promoters of induced 
osteoblast marker genes Alp 79  and Ocn  73 , so Dlx5 appears to possess a duality 
of roles during osteoblast differentiation, both as a direct regulator of Runx2 
transcription, as well as a cooperative transcription factor at Runx2 target genes.  
Molecular signaling and the vertebrate skeleton – The Wnt pathway 
Wnts are secreted, lipid-modified glycoproteins that activate cell surface 
receptor-mediated signal transduction pathways to regulate a variety of cellular 
activities, including cell fate determination, proliferation, migration, polarity, 
and gene expression 80 . In canonical, β-catenin-dependent WNT signaling, a Wnt 
ligand binds to binds to a Frizzled receptor and their co-receptors low-density 
lipoprotein receptor-related protein 5 (LRP5) or LRP6 to stabilize cytosolic β-
catenin via inhibition of a ubiquitinating complex. β-catenin then enters the 
nucleus and stimulates the transcription of WNT target genes by interacting 
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with lymphoid enhancer-binding factor 1 (LEF1), T cell factor 1 (TCF1), TCF3 or 
TCF4.  Non-canonical Wnt pathways not utilizing β-catenin include the 
noncanonical planar cell polarity, which also does not employ LRP5 or LRP6, 
and noncanonical Wnt/calcium pathway, which requires modulation of 
intracellular calcium ion levels. These pathways are further separated by their 
choice of ligand; canonical Wnt signaling uses WNT1, WNT3a, WNT8 or 
WNT10b, while noncanonical signaling relies on WNT4, WNT5a or WNT11.  
Recognition of the Wnt pathway’s involvement in bone biology began with 
a punctuation of discovery: in a single year, mutations causing severe alterations 
in bone density were identified in four groups of patients with bone mass 
disorders, pointing to the canonical branch of WNT signaling.  Two of these 
mutations were detected in the LRP5 coreceptor necessary for Wnt signal 
propagation. Loss of function mutations in LRP5 cause the autosomal recessive 
disorder osteoporosis-pseudoglioma syndrome (OMIM# 259770)  81 . Affected 
individuals have very low bone mass and are prone to developing fractures and 
deformation, though they lack any identifiable defects in collagen synthesis, 
anabolic and catabolic hormones, calcium homeostasis, endochondral growth, or 
bone turnover.  A knockout mouse model confirmed the genotype-phenotype 
relationship, and provided insight into the bone mass deficit. Lrp5-/- mice have 
low bone mass compared to their wild type littermates, though this feature was 
only detectable postnatally 82 . Intriguingly, no aberrations in Runx2 expression 
were detected in these mice.  
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The importance of the Wnt pathway in mediation of postnatal bone mass 
was further highlighted by the identification of gain of function mutations in 
LRP5 (G171V), causing an autosomal dominant high bone mass phenotype 83, 84 . 
Molecular investigations recognized the mutation as detrimental for the affinity 
of the protein for the extracellular Wnt signaling antagonists DKK1 85, 86  and 
SOST 86, 87 . Sost itself is a locus for mutations affecting bone mass. Premature 
termination mutations in Sost 88 cause sclerosteosis (OMIM #605740) whereas a 
52 kb homozygous deletion downstream of the SOST gene is associated with van 
Buchem disease 89 both of whom are characterized by bone overgrowth. 
Genetic analysis in the decade following these initial discoveries detailed 
the importance of many additional canonical Wnt components (β-catenin, Gsk-
3ß, Axin2, and Dkk1; reviewed in 90 ) in both osteoblast differentiation and 
postnatal bone mass density maintenance. Conditional deletion of -catenin 
forces a chondrocytic fate on skeletal precursor cells 91, 92 , a fate suppressed in 
these progenitors in response to ectopic activation of Wnt signaling 91, 93, 94 .  
However, finer dissection of this process reveals the stage of differentiation as a 
strong determinant of the response of a differentiating osteoblast to Wnt 
signaling. β-catenin stabilization in MSCs promotes proliferation at the expense 
of osteoblastic differentiation, while committed osteoblasts respond to the same 
stimulus by accelerating both growth and differentiation, at the expense of 
failure of terminal differentiation into mature osteoblasts.  One possibility 
responsible for this state dependent response is the complex relationship 
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between Wnt signaling and the master regulatory transcription factors Runx2 
and sp7. While the Runx2 P1 promoter possesses a Wnt responsive element that 
recruits β-catenin and TCF/LEF transcription factors 95 , cells lacking β-catenin, 
are, like Lrp5-/- mice, still capable of expressing Runx2 in cells surrounding 
developing bone tissue. This suggests that other inputs in the Runx2 regulatory 
apparatus are sufficient to induce the primary osteoblast differentiation genetic 
program in the absence of Wnt.  
Consistent with their effects on mature bone, the regulatory relationship 
between sp7 and the Wnt pathway appears to be reciprocal. While canonical Wnt 
signaling promotes both osteoblast differentiation and proliferation, sp7 
promotes differentiation of maturing osteoblasts, while inhibiting their 
proliferative potential. It appears that this is accomplished at least partially by 
an sp7-mediated inhibition of Wnt activity.  Sp7 appears to control the 
expression of the extracellular Wnt antagonist Dkk1 by direct binding to its 
promoter, and its expression is indeed abolished in sp7-null embryonic calvarial 
cells. Sp7 also inhibits -catenin mediated transcription by direct interaction 
with the transcription factor TCF1. Therefore, it has been speculated that 
repeated downregulation of Wnt signaling is essential for balancing proliferative 
and cell fate priorities during osteoblastogenesis 96 . 
Molecular signaling and the vertebrate skeleton – The FGF pathway 
Fibroblast growth factors (FGFs) are a family (22 members in both mouse 
and human) 97  of secreted growth factors with roles in diverse biological 
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processes that exert signaling activity by binding to tyrosine kinase fibroblast 
growth factor receptors (FGFRs), inducing intracellular pathways such as p38 
MAPK, PLC, ERK1/2 or PI3K/AKT. Current thinking places the FGF signaling 
axis as a positive regulator of proliferation of progenitor cell populations and 
growth plate maturation during bone development 98 . In cell culture, FGF 
signaling increases proliferation of immature osteoblasts while simultaneously 
blocking differentiation 99, 100 . 
The identities of and roles of specific Fgf ligands at discrete stages of 
skeletal development are poorly understood.  Fgf9 is expressed in early 
mesenchyme condensations prior to ossification, while Fgf2, Fgf5, Fgf6, and Fgf7 
are expressed in the mesenchyme surrounding the ossification. All Fgfs have 
been identified in the coronal suture of E17.5 embryos, save for Fgf3 and Fgf4. 
While in vitro evidence has shown the capacity for Fgf ligands to stimulate 
osteoblast differentiation and or marker genes 101 , animal models have failed to 
provide striking evidence of the necessity of a given ligand for a skeletal process, 
though it is clear that excessive ligand disrupts proper development.  The 
construction of an Fgf2 knockout mouse provided an early illustration of this 
concept.  Fgf2-/- mice are normal in apperance, but have lower bone mass density, 
concomitant with decrease thymidine incorporation in calvarial osteoblasts, 
suggesting an early proliferation defect behind the adult phenotype 102 . 
Consistent with these observations, overexpression of Fgf2 in mice results in 
premature mineralization, achondroplasisa and shortening of the long bone 103  
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Similar observations were made in experments using Fgf9 knockout and 
transgenic mice 104, 105 .   
As is not the case for the FGF ligands, there exists much human genetic 
evidence regarding the necessity of the FGFR genes in skeletal development.  Of 
the four FGFRs, FGFRs1-3 are expressed in calvaria mesenchyme. Gain of 
function missense mutations in FGFR1, FGFR2, and FGFR3 cause a spectrum of 
fourteen disorders, most of whom share a craniosynotosis or chondrodysplasia 
feature 106 . Despite the diversity in phenotypes resulting from those mutations, 
then, it makes sense to try to understand the common biology in these in these 
conditions. Craniosynotosis and chondrodysplasia differ fundamentally in the 
physiological process disrupted in their pathology. Craniosynostosis is a failure 
of the flat bones of the craniofactial skeleton to delay differentiation in 
progenitor cell populations, resulting in premature fusion of the sutures.  
However, chondrodysplasia is a defect in endochrondral ossification, often 
resulting in shortening of the long bones of the limbs and the axial skeleton in 
general. So despite affecting two distinct pathways to mature bone, upregulation 
of FGF signaling in developing skeletal tissue results in a common cell biology 
defect: premature differentiation of progenitor cells.  
Genetic origins of the vertebrate skeleton – Signaling crosstalk 
While understanding the functions of individual signaling pathways in 
bone development is a necessary effort towards a complete theory of 
skeletogenesis, these deconstructions, in isolation, lead to an impoverished view 
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of a highly integrated process. Therefore, it is necessary to consider how these 
pathways interact, either to enhance or police each other’s activities. Therefore, I 
will discuss known connections of each of the systems discussed above.  
Signaling crosstalk in the vertebrate skeleton - BMP and Wnt pathways 
 Studies investigating interactions between Wnt and BMP in osteoblast 
differentiation have identified both synergistic and epistatic relationships 
between components of these pathways. At a fundamental level, BMP-2 driven 
osteogenesis is dependent on the presence of -catenin  107 . Many examples exist 
of synergistic activation of osteoblast marker genes by costimulation with BMP 
and Wnt ligands at early stages of osteoblastogenesis 107-109 . Several possible 
explanations involving intracellular mediators of these signals have been 
proposed. In Xenopus embryos and cos-7 cells, Wnt signaling extends the 
duration of a ‘pulse’ of BMP signaling by regulating SMAD1 activity via GSK-3 
dependent phosphorylation 110 . Other researchers have described a mechanism 
involving the physical interaction of SMAD4 with TCF4 and the general co-
activator protein p300 111 . 
However, at later stages in bone biology, they may have distinctly 
antagonistic roles. Where continued Wnt signaling is crucial for maintaining 
sufficent levels of bone mass density, BMP signaling at this stage actually acts in 
an catabolic manner. Deletion of Noggin, which codes for an extracellular 
inhibitor of BMP ligands, led to decreased bone mineral density (BMD) and bone 
formation in mice 112 . The extracellular Wnt inhibitors Dkk1 and Sost are 
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downstream of BMP signaling 113 , and through their upregulation, Wnt signaling 
is attenuated. Genetic evidence for this interaction was observed in an 
osteoblast-specific Bmpr1a knockout mouse, which had a high bone mass 
phenotype concomitant with upregulated Wnt signaling 113 . BMP inhibition of 
Wnt occurs in uncommitted bone marrow cells via sequestration of the GSK-3 
inhibitor/Wnt activator DSH by SMAD1 114 .  
 Another level of BMP and Wnt integration to discuss is the combined cis 
regulation of both component and target genes. Chip-seq data from erythoid cells 
indicate that many active enhancers in these cells recruit both SMAD1 and 
TCF7L2 115 . The promoters of Dlx5 and Msx2, which are routinely and 
essentially upregulated in response to BMP signaling, respond synergistically to 
BMP and Wnt activation. Unsurprisingly, SMAD1, TCF4 and -catenin are 
recruited to these promoters following dual stimulation of these pathways 108 .  
Signaling crosstalk in the vertebrate skeleton - BMP and FGF pathways 
 Unlike the complicated relationship between BMP and Wnt signaling, the 
association between BMP and FGF signaling has been described as largely 
cooperative. Similarly to its relationship with Wnt, many examples exist where 
BMP signaling is in part dependent on the presence of active FGF signaling to 
achieve full osteogenic effect. Mice null for Fgf2 have decreased Bmp2 expression 
116 , while FGF-2 and FGF-9 increase expression of Bmp2 in calvarial osteoblasts. 
Additionally, these ligands inhibit the expression of noggin, an extracellular 
BMP inhibitor normally upregulated in response to BMP signaling 117 .  FGF 
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mediated suppression of noggin is also observed in vivo in the coronal dura 
mater during suture development. Noggin maintains the patency of flat bone 
sutures in the skull, so it is possible that some of the craniosynostosis phenotype 
arising from gain of function FGFR mutations is due, in part, to coordinately 
misregulated BMP signaling 116, 118 . FGF also upregulates BMP signaling beyond 
the context of increasing ligand-receptor association; Fgf2-/- osteoblasts have 
impaired colocalization of phosphorylated SMADs and RUNX2 in response to 
BMP-2 signaling, though the reason for this deficit is unclear 116, 119 .  Finally, 
FGF-2 and BMP-2 have a synergistic effect on fracture healing: FGF-2 has a 
critical function at early stage while BMP-2 promotes mineralization at later 
stage 120 . 
Signaling crosstalk in the vertebrate skeleton – Wnt and FGF pathways 
 Wnt and FGF signaling have opposing effects during osteoblast 
differentiation 121 . The convergence of Wnt and FGF signaling in skeletogenesis 
occurs primarily by the suppression of Wnt signaling by FGF signaling. Multiple 
mechanisms have been described underlying this process. At a fundamental 
level, the expression of components of the canonical Wnt pathway requires FGF 
signaling. mRNA expression of Wnt10b, Lrp6, and -catenin are significantly 
downregulated in bone marrow stromal cells from Fgf2-/- mice 122 . Exogenous 
application of Fgf2 ligand to these cells rescues both the osteogenesis defects 
while increasing -catenin stabilization and nuclear localization. Comparative 
microarray analysis of osteoblasts derived from patients with gain of function 
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FGFR2 mutations identified the transcription factor SOX2 as dramatically (15 to 
121 fold) upregulated compared to wildtype cells 99 . Coimmunoprecipitation 
experiments demonstrated that SOX2 associates with -catenin in osteoblasts 
and can repress activity of a reporter plasmid drive by TCF/LEF binding sites.  
 Wnt and FGF signaling interactions have also been studied genetically in 
the context of skull suture formation. Tellingly, deletion of the gene encoding the 
Wnt negative regulator, Axin2, resulted in a phenotype similar to that observed 
in craniosynostosis in FGFR gain of function mutations 123 . Upregulation of Wnt 
signaling in Axin2-deficient mice was confirmed by increased nuclear 
accumulation of -catenin. In concert, the proportion of FGFR positive cells at 
the suture was significantly reduced 124 . Further altering the FGF/WNT balance 
by generating Axin2-/-, Fgfr1+/- mice produce sutures with ectopic cartilage 
formation 125 . Cells at the front of these sutures had upregulated BMP signalling, 
as evidenced by increased SMAD phosphorylation. A complex mechanism in 
suture mesenchyme has been proposed, where Wnt signaling expands the 
population of skeletal precusors, while stimulating BMP signaling to counteract 
FGF signaling. In the presence of relatively high levels of FGF signaling, BMP 
signaling promoters osteoblastogenesis in the microenvironment, while reduced 
FGF signaling results in the effect of BMP to signaling to promote a chondrocytic 
fate.  
 
Zebrafish as a model to study vertebrate skeletogenesis 
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 Zebrafish enjoy a burgeoning status as a more tractable alternative to the 
standard skeletal biology models of mouse and chick126. Development of both the 
craniofacial127 and axial128 skeletons has been well characterized. Zebrafish 
produce the same skeletal cell types as higher vertebrates, albeit in simpler 
patterns129. Additionally, gene expression events in skeletal elements are 
orthologous to those observed in higher vertebrates130. Specifically for the 
purposes of this work, both zebrafish runx2 orthologs, runx2a and runx2b are 
expressed in nascent skeletal elements131. Moreover, the appearance of the 
zebrafish skeleton is rapid; the first bony structure, the cleithrumd, is visible 
within 72 HPF132, though expression of bone marker genes in the anlagen begins 
at approximately 36 HPF133.  Potential bone specific deficiencies of the system, 
such as the lack of osteocytes or hematopoietic activity in the bone marrow, are 
not hindrances for exploring early development134.  
 
Study aims 
Despite the identification of skeletogenesis specific roles of the signaling 
pathways discussed above and otherse, a coherent narrative of the genetics and 
cell biology underlying this process still eludes the field. Because of its singular 
                                                          
d Most of the imaging in this document will focus on two bones as proxies for the 
expression in the rest of the skeleton. The cleithrum is a bone of mesodermal origin, and 
is roughly analogous to the shoulder girdle in mammals. Conversely, the opercle is 
derived from neural crest, and adopts a fan shaped morphology to lend structural 
support to the gill flap.  
e These include Notch, Indian Hedgehog, calcineurin, retinoic acid, p38 MAPK, among 
others.  
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role in both marking and initiating early stages of osteoblastogenesis, 
understanding the regulation of Runx2 itself is a potentially fruitful approach to 
understanding the biology of this process. Therefore, the rest of this document 
will be committed to describing the cis regulatory architecture responsible for 
regulating both the presence of the RUNX2 transcription factor itself in putative 
skeletal cells, but also the modulation of gene dosage that is so critical for proper 
execution of this process. Chapter 2 describes the results of a conservation based 
screen for conserved non-coding elements associated with the human RUNX2 
locus capable of directing expression to bone. Chapter 3 relates a series of 
functional studies on individual elements, identifying upstream regulators with 
previously confirmed roles in skeletogenesis. Finally, Chapter 4 integrates the 
results from Chapters 2 & 3 for a summary, discussion of the implications of the 
work, and suggestions for future avenues of experimental inquiry informed by 
this effort.  
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CHAPTER 2 
 
A SCREEN FOR RUNX2 ASSOCIATED 
ENHANCERS IDENTIFIES THREE CONSERVED 
NON-CODING ELEMENTS CAPABLE OF 
DIRECTING EXPRESSION TO OSTEOBLASTS IN 
VIVO. 
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CHAPTER 2  
Introduction 
 The gene encoding the transcription factor RUNX2 was identified as the 
underlying cause of the human skeletal syndrome cleidocranial dysplasia (CCD) 
24, 126 , resulting from haploinsufficiency. RUNX2 regulates expression of 
downstream genes important for osteoblast function, and its forced expression 
can upregulate those target genes 25 . Mutation of the mouse gene demonstrated 
the requirement for Runx2 in bone formation throughout the skeleton, and its 
continued expression is also required for normal bone homeostasis 22, 127 .  
 The years since its identification have yielded a detailed understanding of the 
pathway downstream of Runx2 leading to differentiated osteoblasts, with 
identification of many genes whose transcription is directly regulated by Runx2. 
Comparatively, almost nothing is known about the transcriptional regulation of 
Runx2 itself. This is a critical question, since initiation of Runx2 expression in 
development determines when and where bones will form, and its ongoing 
expression is important for proper maintenance of bone throughout life. 
Numerous signaling pathways have been implicated in its induction, but none 
has been shown to directly regulate Runx2 transcription in vivo 128 .  
 Direct regulation of a gene is accomplished by the binding of diffusible trans 
regulatory factors, either directly or to other trans factors, to cis-regulatory 
elements (CREs) 129 . CREs are regions of genomic DNA with some role in 
activating, maintaining, or repressing transcription of an mRNA product. 
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Elements containing or immediately adjacent to the one of the transcriptional 
start sites of a gene are generally classified as promoters. They mark the site of 
recruitment of RNA polymerase and melting of the DNA strand and 
consequently possess an innate directionality.  Conversely, enhancers can 
positively regulate gene transcription without regard to DNA strand orientation, 
and may be located at either a great distance from the transcriptional start site 
or, potentially on other chromosomes altogether 130, 131 , though this is not known 
to be a common phenomenon in vertebrate genomes. Additionally, exons of 
neighboring genes can also function as enhancers 132, 133 . Other forms of cis 
regulatory elements include locus control regions and silencers, capable of 
preventing gene activation and insulators, which form boundaries to prevent the 
spread of a repressive heterochromeric chromatin environment through the 
association of the CTCF protein.  
 Runx2 is somewhat noteworthy in that it possesses two distinct 
promoters. The proximal P2 promoter regulates the type I isoform, while the 
distal P1 promoter (Runx2 P1) regulates the type II isoform. The two proteins 
share the same functional domains and are similarly capable of transactivating 
target genes 134 . The P2 promoter is active at a basal level in a broad number of 
cells and tissues, including the thymus, cartilage, periosteum, and suture tissue 
of the calvarium 135-137  whereas the P1 promoter is active in hypertrophic 
chondrocytes and mature osteoblasts 25, 138 . Although in vivo, transcription from 
both promoters are necessary for fine-tuning Runx2 expression 139 , they are 
 25 
 
incapable of directing proper expression of a reporter transgene by themselves 140, 
141 , indicating the existence and necessity of a more elaborate cis regulatory 
architecture. Also, while most characterized CCD mutations affect the RUNX2 
coding sequence, some cases have been associated with translocations of distal 
regions 142, 143  or have no identified coding sequence 66  mutations, suggesting the 
presence of critical regulatory sequences whose mutation or disruption severely 
impairs gene expression. 
 Therefore, I hypothesized that there must exist additional enhancer elements 
necessary to direct Runx2 expression 144 . Methodologies for identifying functional 
CREs are an area of ongoing inquiry in the literature, each possessing relative 
strengths and inherent limitations.  In a developmental context, the current 
‘gold standard’ experiment for confirming regulatory potential of a DNA region is 
the deletion of that element in the germline or a relevant integrated BAC in vivo 
and confirmation of a phenotypic of transgene expression change. The chief 
advantage of the approach is the opportunity to observe an element in its native 
regulatory environment in a variety of tissue types. Unfortunately, isolating 
individual elements using germline modifications in mice is costly and time 
consuming. Additionally, functional redundancy between elements may mask or 
buffer the consequences of element loss.  
 Other methods rely on the flood of bioinformatic data that has been made 
available as the result of numerous genome sequencing projects as well as 
massively parallel sequencing technologies 145 . Current estimates place 
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approximately 5% of the human genome under negative purifying selection 146, 147 , 
where evolutionary forces conserve sequence against the caprice of mutation. 
However, only 1.5% of the genome appears to have exonic coding potential. The 
difference between these proportions—popularly referred to as the ‘dark matter’ 
of the genome—is due to the relative difficulty of annotating aspects of genes 
without protein coding potential. Conservation based methods assume conserved 
non-coding elements possess functional importance whose ablation or alteration 
would have fitness consequences. While conservation is a generally reliable and 
accepted criterion for identifying candidate CREs associated with a given gene, 
there has not yet been an agreement in the field regarding the algorithm or 
parameters that are best suited for identifying CREs amongst diverse biological 
contexts 129 . Notably, deletion of many ‘ultraconserved’ elements in mice resulted 
in no observable phenotype 148 . Additionally, while conservation might be a good 
approach to discern sites of input for relatively ancient signaling connections, it 
is less useful at identifying newly arisen CREs, which are likely to be of the 
greatest interest from a evolutionary perspective. 
 Marrying chromatin immunoprecipitation with genome wide interrogation 
techniques such as microarrays and next generation sequencing permits the 
mapping of locations of both known transcription factors as well as histone 
modifications associated with regulatory activity to the genome in a variety of 
cell types and environmental situations.  In particular, enrichment of 
methylation of 4th lysine of the N-terminus of the histone H3 has been repeatedly 
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shown to be a powerful technique for locating promoters (H3K4me3) and 
enhancers (H3K4me1/2) in the absence of detectable sequence conservation 149, 150 
. However, these approaches are generally poorly suited for study of enhancers 
involved in development, because of cell number requirements of precious 
embryonic materials as well as their necessarily static nature. 
 With these experimental approaches and limitations in mind, I decided rely 
on moderate conservation amongst vertebrates to identify CREs associated with 
the human RUNX2 locus. A list of candidate CREs was generated by 
interrogating the locus using PhastCons 151 , an algorithm which relies on 
multiple vertebrate genomes to both identify conserved elements, as well as a 
quantitative measure of the evidence of that conservation, permitting a ranking 
and prioritization of element testing. Because location is a poor predictor of 
regulatory function, and enhancers can exist at great distances from their 
associated genes, I examined sequences in an interval of >1 Mb containing 
human RUNX2.   
 Finally, the qualities of the systems used to actually confirm regulatory 
activity merits discussion. Especially in developmental contexts, in vivo systems 
are preferable to cell based assays because of the ability to simultaneously 
observe the full range of likely dynamic regulatory activity in all tissues. 
Traditionally, mice have been used for this purpose, but for the reasons 
discussed above, these are a difficult choice for studying embryonic expression, 
as it requires sacrificing a transgenic animal at each time point of interest. 
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Additionally, because many transgenes show position dependent effects resulting 
in ectopic activation in cells that do not actually reflect biological reality, it is 
necessary to examine a number of embryos to ensure that uniform and robust 
pattern of expression can be elucidated. In contrast, zebrafish produce hundreds 
of optically accessible embryos in single clutch. Finally, a highly efficient 
transgenesis methodology based on the Tol2 transposase permits the 
construction of potentially hundreds of mosaic transgenic fish in a single 
morning 152 .  
Specifically to skeletal biology, zebrafish are increasingly being employed as an 
alternative to the standard models of mouse and chick 153 . In addition to the 
reasons of tractability listed above, they produce the same skeletal cell types as 
higher vertebrates, albeit in simpler patterns. The appearance of the zebrafish 
skeleton is rapid; the first bone, the cleithrumf, is visible within 72 HPF 154 , 
though expression of bone marker genes in the anlagen begins at approximately 
36 HPF 155 .  Potential bone specific deficiencies of the system, such as the lack of 
osteocytes or hematopoietic activity in the bone marrow, are not hindrances for 
exploring early development 156 .  
In this chapter, I describe a screen for RUNX2-associated CREs in the human 
genome. Candidates were selected on the basis of moderate conservation 
                                                          
f Most of the imaging in this document will focus on two bones as proxies for the 
expression in the rest of the skeleton. The cleithrum is a bone of mesodermal origin, and 
is roughly analogous to the shoulder girdle in mammals. Conversely, the opercle is 
derived from neural crest, and adopts a fan shaped morphology to lend structural 
support to the gill flap.  
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amongst vertebrates and tested for in vivo activity in a zebrafish system. 
Commonalities and differences in expression domains are also noted.  
Materials and Methods 
 Ethics statement. All animal work was conducted according to national and 
international guidelines, and with the knowledge and approval of the 
Institutional Animal Care and Use Committee of the University of Pennsylvania. 
 Identification of conserved non-coding elements associated with RUNX2. To 
identify sequences for in vivo analysis, the candidate locus (hg18; chr6: 
44904448-45974166) was interrogated for conserved non-coding elements, as 
defined by the PhastCons Vertebrate Conserved Elements track during January, 
2010 151 . Elements overlapping known RefSeq exons were excluded from further 
analysis. The top 50 scoring elements (LOD >454) were amplified by PCR (Table 
1) from human genomic DNA with LA Taq polymerase (Takara), and cloned into 
the Tol2 transposon containing vector pattP-Tol2-EGFP as previously described 
152 . 
 Transgenesis and expression analyses. Fish were cared for following standard 
protocols. Each construct for analysis was injected as previously described in at 
least two separate experiments, and mosaic expression of eGFP analyzed in a 
minimum of 150 embryos 157 . Embryos were screened from 1- 5 DPF using a 
Zeiss V12 Stereomicroscope, and imaged with AxioVision 4.5 software. For those 
constructs regulating a consistent expression pattern, embryos were raised to 
adulthood and their progeny examined for expression after germline 
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transmission. All constructs were examined in at least three independent 
transgenic lines for consistent expression. The +210RUNX2:mCherry construct 
was made in a version of the same vector with mCherry coding sequence instead 
of eGFP. sp7:mCherry fish were made by injection of a modified BAC containing 
medaka sp7 regulatory sequences, a kind gift from Christoph Winkler 158 . 
 Confocal imaging. Embryos were anesthetized in Tricaine and mounted in 
MatTek glass bottom culture dishes in 1% low melt SeaPlaque agarose. Images 
were acquired on an Olympus IX 81 microscope equipped with a Yokogawa CSU 
10 scan head combined with a Hamamatsu EMCCD camera (model C9100-13, 
Bridgewater, NJ). Hardware was controlled by Slidebook version 5.0 (Intelligent 
Imaging Innovations). Diode lasers for excitation (488 nm for eGFP and 561 nm 
for mCherry) were housed in a Spectral Applied Research launch (Richmond 
Hill, Ontario). Confocal image stacks were processed with ImageJ 
(http://rsbweb.nih.gov/ij).  
 In situ hybridizations. Whole mount in situ hybridizations were performed as 
described 159 , with the following modifications: 0.05% CHAPS detergent was 
added to the pre-hybridization and hybridization solutions to prevent embryo 
clumping, and the concentration of NBT was reduced 10-fold in the staining 
solution to permit overnight development with low background. Stained embryos 
were dehydrated by successive methanol washes, cleared in methyl salicylate, 
and mounted in Permount medium (Fisher; SP15-100) between bridged 
coverslips. Microscopy was performed on an Olympus BX51 with Nomarski 
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optics. Images were acquired using Spot Basic version 4.6 (Diagnostic 
Instruments). Further adjustments to white balance and contrast were 
performed with Adobe Photoshop. 
Quantitative PCR. RNA was extracted from whole zebrafish embryos as 
previously described 160 . cDNA was synthesized using the cDNA high capacity 
transcription kit (Invitrogen). qPCR was performed in 20 µl reactions using ABI 
Sybr Green Master mix, and 250M primer concentration. Samples were 
amplified using an ABI StepOnePlus real time PCR system. 
Identification of cis regulatory elements associated with the zebrafish 
orthologs runx2a and runx2b. The program WPH finder was downloaded from 
http://rana.lbl.gov/downloads/wph.tar.gz. The three characterized human 
enhancers (-460RUNX2, +210RUNX2 and +542RUNX2) were used as substrates 
to build word profiles based on the occurrence of 8-mers. These were individually 
used scan the loci containing the zebrafish Runx2 orthologs runx2a (chr17: 
5385672-5740215;Zv8) and runx2b (chr20: 44206838-44359224;Zv8) using 250 
base pair windows offset by 100 base pairs. Repetitive sequences were removed 
with RepeatMasker prior to scanning. An arbitrary cut off of Z>5 determined 
which candidate elements to progress to functional testing.  
Results 
A screen for RUNX2 associated enhancers identifies three conserved non-coding 
elements capable of directing expression to osteoblasts in vivo. 
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As potential cis–regulatory elements for RUNX2, we selected the 50 most 
conserved non–coding sequences within the ~1Mb interval bounded by the 3' 
UTR of the overlapping gene SUPT3H and the 3' UTR of the downstream gene 
CLIC5  in the human genome(Figure 1). We grouped proximate sequences into 
larger amplicons, resulting in 36 constructs (Table 1). Each sequence was tested 
for in vivo enhancer activity, through its ability to direct tissue–specific eGFP 
expression in zebrafish. We initially screened by examining approximately 150 
mosaic injected embryos for fluorescence from 1-6 days post fertilization (DPF); 
constructs positive in the initial screen were passed through the germline for 
detailed characterization. 
 In total, I identified three enhancers capable of directing reporter gene 
expression to osteoblasts: a distant upstream enhancer located in the last intron 
of SUPT3 (-460RUNX2)g, a downstream enhancer in the intergenic space 
between RUNX2 and CLIC5 (+542RUNX2), and one in the last intron of RUNX2 
itself (+210RUNX2).  
Comparison of transgene activity by confocal microscopy and in situ 
hybridization reveals distinct, yet redundant expression patterns. 
 While all three enhancers direct expression to osteoblasts, they do not have 
identical activities. Prior to formation of the first bones, +210RUNX2 is 
transiently active in the branchial arches, as evidenced by GFP expression in 
                                                          
g The nomenclature used here and subsequently in this document to identify specific 
enhancer elements is the distance from the transcriptional start site of a gene in 
kilobases, relative to the directionality of the open reading frame. 
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live embryos at 2DPF(Figure 2.2j).  An earlier and less enduring expression in 
the branchial arches is directed by +542RUNX2 between 24-48 HPF  (data not 
shown). +542RUNX2:eGFP expression is first detectable in the cleithrum 
anlagen between 28-32 HPF, while this activity is relatively delayed in embryos 
carrying the other two transgenes (Figure 2.3a,d). Referring to the confocal data 
at 3DPF shows that, again, while all three transgenes drive expression in 
cleithrum in osteoblasts, the expression is much more pronounced in the 
+542RUNX2:eGFP (Figure 2.2f) and -460RUNX2:eGFP lines (Figure 2.2o). 
Furthermore, +542RUNX2 mediated expression in the cleithrum at this stage is 
uniform along the dorsal ventral gradient, while in -460RUNX2, expression is 
relatively punctuated at the dorsal and ventral extremes of the bone. 
 All three enhancers are active in cells of the opercle (Figure 2.4), a neural–
crest derived bone 161  that forms by membranous ossification lateral to the 
branchial arches. However, +210RUNX2 directs expression to the 
osteoprogenitors surrounding the edges of the bone (Figure 2.4j,m,p), while the 
activity of the other two enhancers is confined to cells within the bone itself. 
Similarly to the expression differences observed in the cleithrum, +542RUNX2 
directs expression uniformly throughout the bone (Figure 2.4s,v,y), while 
+460RUNX2 expression is enhanced in the strut and fan structures of the 
opercle (Figure 2.4 a,d,g) 
+154runx2a, the zebrafish ortholog of +210RUNX2, is conserved at the levels of 
sequence and function. 
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  While identifying conserved enhancers between distantly related species is 
not always a straightforward effort, alignment of vertebrate genomes using 
MultiZ 162  in the UCSC genome browser revealed apparent linear alignment 
delement, +154runx2a, directs expression the branchial arches at 3DPF (Figure 
2.5 a) as well as to bony elements such as the opercle and branchiostegal rays at 
5DPF (Figure 2.5 b,e).  
Only +542RUNX2 directs expression to the developing vertebrae. 
 Later in zebrafish development (10-21 DPF), the vertebrae form from 
migrating sclerotome cells that surround the spinal cord 163 . Though at 5DPF, all 
three enhancers direct expression to all visible skeletal structures, the ability to 
direct expression to the vertebral arches at 14DPF is limited to +542RUNX2 
(Figure 2.6c). Some expression by -460RUNX2:eGFP is visible in the centra of 
the vertebrae. (Figure 2.6a). +210RUNX2 failed to direct expression to any 
aspect of the vertebral column (Figure2.6b). 
Chromatin features of identified enhancers. 
 As discussed in the introduction, enhancer associated chromatin marks are 
an often-employed method to identify loci with regulatory activity in a cell or 
tissue type being studied.  There exists an unpublished, publicly available ChIP-
Seq data set from a normal human osteoblast cell line as part of the ENCODE 
projecth. Enrichment for regulatory element associated marks (H3K4me1, 
                                                          
h According the documentation accompanying the data set, the cell line is normal 
human osteoblasts (NHOst) from Lonza (#CC-2538). The ChIP-Seq data was 
produced by a collaboration of Bradley Bernstein and Greg Crawford. 
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H3K4me2, H3K27Ac) was examined as well as recruitment of the enhancer 
associated coactivator p300 (Figure 2.7). +542RUNX2 and +210RUNX2 were 
significantly enriched for p300, as well as H3K4me1 and H3K4me2, and were 
identified as peaks in the data set as determined by a hidden Markov model 
algorithm. Curiously, no enrichment for any of the studied histone modifications 
or proteins was observed in -460RUNX2. 
The three RUNX2-associated enhancers contain enough information content to 
efficiently identify other skeletal specific enhancers in a non-conservation based 
approach. 
  With the limitations of conservation based approaches to discovering 
CREs in mind, I wanted to explore whether other methodologies might be 
efficient at identifying enhancers associated with the zebrafish RUNX2 
orthologs, runx2a and runx2b, for which there are few alignable genomes 
available to detect conservation. One such strategy involves utilizing the 
information content of known enhancers as a basis for predicted new ones from 
untested sequence data. WPH Finder is such an algorithm that has been 
successfully used to recognize enhancer elements not identifiable by linear 
conservation between Drosophila species 164 . It trains itself by counting the 
occurrence of specific eight letter DNA ‘words’ (which likely correspond to 
transcription factor binding sites, or other features conferring regulatory activity 
upon an element), forming a profile of these word, and then testing windows of 
candidate sequences for overrepresentation relative to it. 
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 Using this methodology, the loci of the zebrafish Runx2 orthologs, runx2a and 
runx2b were scored for word profile similarity to the each of the three known 
human enhancers (Tables 2.2. 2.3). Eighteen candidates were tested from the 
runx2a locus, and ten were examined from that of runx2b. In contrast to the 
relatively low rate of skeletal enhancer activity identified in conserved 
candidates from the human locus (3/38 = 7.8%), 38.9% (7/18) of amplicons tested 
from the runx2ai locus and 50% (4/10) of those from runx2b showed some pattern 
of skeletal expression (Figure 2.8a,b). Notably, almost all of the positive elements 
(11/12) fall within the coding region of either one of the Runx2 orthologs, or 
supt3h, whose syntenic relationship with Runx2 is ancient. Representative views 
of expression patterns of these elements show expression in both subsets of 
osteoblasts as well as cartilaginous structures (Figure2.8c-h).  
 
 
 
 
 
                                                          
i These numbers exclude +154runx2a, which had already been shown to regulate a 
skeletal expression pattern.  
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Figure 2.1. – Broad distribution of osteoblast specific enhancers at the 
RUNX2 locus. The RUNX2 locus (chr6: 44,904,448-45,971,166, hg18) as 
represented in the UCSC Genome Browser is shown, with the conserved non–
coding elements tested for enhancer assay indicated at top. Elements testing 
positive for osteoblast expression in vivo are shown in green, while those with no 
activity in skeletal tissues are indicated in red. Tracks displaying all conserved 
elements as defined by PhastCons amongst vertebrates and mammals are 
displayed at the bottom of the figure to visualize relative conservation across the 
genomic region. 
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Figure 2.2 -- Expression patterns of three human RUNX2 associated 
enhancers. Lateral views of doubly transgenic zebrafish embryos for sp7:mCh 
and -460 RUNX2:eGFP (A-I), +210RUNX2:eGFP (J-R), and +542RUNX2 (Q-AA)  
were imaged at 2DPF and 3DPF. In 2DPF embryos, coexpression of sp7:mCh 
and -460RUNX2:eGFP (A) and +542RUNX2 :eGFP (S) in the developing 
cleithrum, but not in +210RUNX2 (J). Conversely, branchial arch expression in 
+210RUNX2:eGFP is apparent at 2DPF. All three RUNX2 transgenes express in 
the opercle anlage at 3DPF with sp7:mCh (D,M,V). Ventral views imaged at 
5DPF demonstrate concomitant RUNX2 transgene expression in later 
ossifications (G,P,Y).ba, branchial arches; bs, brachiostegal ray; cl, cleithrum; de, 
dentary mx, maxilla; op, opercle; Scale bar = 50 mm 
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Figure 2.3 -- Differential expression initiation times in the cleithrum 
anlagen.  Embryos from each transgenic line were fixed at 4 hour intervals and 
analyzed by in situ hybridization with an eGFP probe to determine onset of 
expressing in the cleithrum.  Dorsal views of representative embryos of 
+542RUNX2:eGFP (a,d), +210RUNX2:eGFP (b,e) , and +542RUNX2:eGFP (c,f). 
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Figure 2.4 – Distinct expression domains in the developing opercle. 
Lateral views of the opercle in doubly transgenic zebrafish embryos for sp7:mCh 
and (a-i), -460 RUNX2:eGFP (j-r) +210RUNX2:eGFP, and (q-aa)  +542RUNX2 
were imaged at 3DPF, 4DPF and 5DPF; Scale bar = 10 mm 
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Figure 2.5 – +154runx2a, a conserved ortholog of +210RUNX2, directs 
expression to the branchial arches and osteoblasts. Lateral (a-d) and 
ventral (e-g) of doubly transgenic zebrafish for +154runx2a:eGFP and 
+210RUNX2:mCh at 3DPF(a) and 5DPF (b-g). ba, branchial arches; bsr2, 
brachiostegal ray 2 bsr3, brachiostegal ray 3; op, opercle; 
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Figure 2.6 -- +542RUNX2 directs expression to the developing vertebral 
arches. Lateral views of the developing vertebrate column of doubly transgenic 
zebrafish for the indicated RUNX2:eGFP transgene and sp7:mCh at 14 DPF. -
460RUNX2:eGFP expression (a) is directed to the anterior edge of the 
presumptive vertebrate. +210RUNX2:eGFP (b) does not express in any portion of 
the anatomy and +542RUNX2:eGFP (c) directs expression to the vertebral 
arches. (d-f) demonstrate sp7:mCh mediated expression; (g-i) shows a merge of 
these two pattern, 
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Figure 2.7 – Analysis of chromatin environment at three RUNX2 
associated enhancers in a normal human osteoblast cell line.  The human 
skeletal enhancers -460RUNX2 (a), +210RUNX2 (b), +542RUNX2 (c) are shown 
as represented in the UCSC genome browser along with tracks indicating both 
the enrichment of and presence of peak of the following histone 
modification/proteins in normal human osteoblast cell lines as defined by ChIP-
Seq. 
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Figure 2.8 – Screen for skeletal enhancers associated with the zebrafish 
Runx2 orthologs, runx2a and runx2b. The runx2a(a; chr17: 5385672-
5740215;Zv8) and runx2b(b; chr20: 44206838-44359224;Zv8) loci(chr6: 
44,904,448-45,971,166, hg18) as represented in the UCSC Genome Browser is 
shown, with the elements tested for enhancer assay indicated at top. Elements 
testing positive for skeletal expression in vivo are shown in green, while those 
with no activity in skeletal tissues are indicated in red. Tracks displaying all 
conserved elements as defined by 6 way MultiZ alignment displayed at the 
bottom of the figure to visualize relative conservation across the genomic region. 
Representative images of transgenic fish carrying these elements illustrate the 
diversity of skeletal expression observed. -52runx2a:eGFP (c) expresses in a 
subset of ossifying structures at 5DPF; +54runx2b:eGFP (d) expression is 
exclusive to osteoblasts; +28runx2b:eGFP (e) expression is found in the 
cartilaginous elements of the neurocranium; -32runx2a:eGFP (f) expressed in the 
branchial arches as well as the dentary and maxilla forming the mouth; and 
+38runx2b:eGFP (h) expresses in the pharyngeal skeleton and dermal bones. ba, 
branchial arches; bh, basihyal; bs, brachiostegal ray; cb5, ceratobranchial 5; ch, 
ceratohyal; chb, ceratohyal bone; cl, cleithrum; de, dentary; e, ethmoid; mk, 
Meckel’s cartilage; mx, maxilla; op, opercle; pq, palatoquadrate 
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Table 2.1. Sequences at RUNX2 locus tested for enhancer activity. Each 
element is named for the distance in kilobases from the transcription start site of 
RUNX2; the location of each conserved region is given as coordinates in hg19, 
chr6. Where multiple conserved sequences were grouped into one amplicon, the 
LOD scores for each are listed separately. The primer sequences are those used 
to amplify the elements from genomic DNA for testing. The three elements in 
bold are those with activity in osteoblasts.  
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Name 
Coordinates(Zv8
) F primer R primer 
Produc
t size 
(bp) 
Simil
arity 
+321runx2
a 
chr17:5,278,105-
5,278,353 ACAGATGGCGGTGAAGCAGT GCACGTCCGAATGTCAACAA 1061 -460 
+261runx2
a 
chr17:5,338,455-
5,338,703 TGTGAAGCTGCTTTGACACAATC CGGTGTCCTGTTGCTCAGTG 870 +542 
+258runx2
a 
chr17:5,341,255-
5,341,503 CGAGCGTCCATTCACAAACA AGGAAACACTGAAGGACAAAATGC 852 -460 
+229runx2
a 
chr17:5,371,055-
5,371,303 CCCAACGTCGGCTTACGATA TTGCAGTGAGATTGCGTTGG 892 +542 
+206runx2
a 
chr17:5,392,750-
5,393,159 
AGCACCACCACCAACTGGAT 
GGAGCAGCTGAAGAGGCTTG 938 
-
460,+
210 
+179runx2
a 
chr17:5,420,855-
5,421,103 CTAGCGCCATTGCTGGTTTC ATCAGATTCCATGCGGTTCG 991 -460 
+70runx2a 
chr17:5,529,955-
5,530,203 AGCAGTTACGCTTTTGATGGAG ACATATTTGGCGCTCGCAGT 1017 -460 
+20runx2a 
chr17:5,579,405-
5,579,653 TCTGCTGGCCCATAAGAAAAA TCTTGGAGCAACTGGCAAGC 882 -460 
+14runx2a 
chr17:5,585,655-
5,585,903 TTCAATGGACTTTGATTCAGCTT 
CAAGCAGTGACTGACAAATGAAAT
G 852 +542 
+1runx2a 
chr17:5,599,105-
5,599,353 CGGCAGTGATGACAAAACCA TCACCACGACCTGCAGAAGA 895 -460 
-1runx2a 
chr17:5,600,005-
5,600,253 TCCTAAAGCGGGAGCACAAA TGACCCCGAAACAGGAGAGA 865 -460 
-2runx2a 
chr17:5,600,505-
5,600,753 TGTCAGTGGTCCTGCGTTGT TGACTGAAGGCAGTCGACCA 884 +542 
-32runx2a 
chr17:5,632,105-
5,632,353 GGCAACCACAAATTGAAAACC CCGCAACCATACGGGACTAA 1455 +542 
-52runx2a 
chr17:5,651,555-
5,651,803 CTCCCTTCATGGTGGCTTCA CCTCAAACCAGGGCACTAAGAC 949 -460 
-
140runx2a 
chr17:5,740,055-
5,740,303 AGCGATAGAGCCGAGACGTG ACTGAAGCTGCGTCCCAAAA 2456 +542 
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Table 2.2. Sequences at the runx2a locus tested for enhancer activity. 
Each element is named for the distance in kilobases from the transcription start 
site of runx2a. The primer sequences are those used to amplify the elements 
from genomic DNA for testing. The seven elements in bold are those with 
skeletal activity. Similarity indicates the human RUNX2 associated enhancer to 
which WPHFinder identified word profile similarity. 
 
 
 
 
 
 
 
 
-
141runx2a 
chr17:5,741,305-
5,741,553 
CGAACAGACAGATGAATAAAAAGACA
A GCAACCCATCTCTGGGAAAC 1262 +542 
-150runx2a 
chr17:5,750,755-
5,751,003 TGGGCTGGAGACCAAGAAAA TGCATTGCACATAGGGGACA 1192 +210 
-153runx2a 
chr17:5,753,255-
5,753,503 TCCCGAAGATCTGGCAAATG GGCCTGGATGCATCATTTTT 863 +460 
 54 
 
 
 
 
 
Table 2.3. Sequences at the runx2b locus tested for enhancer activity. 
Each element is named for the distance in kilobases from the transcription start 
site of runx2b. The primer sequences are those used to amplify the elements 
from genomic DNA for testing. The five elements in bold are those with skeletal 
activity.  
 
Name Coordinates(Zv8) F primer R primer Product size (bp) 
-45runx2b 
chr20:44,131,047-
44,131,967 TGCGCTCTTTCCAGCAATTT TGGGCACGCTATGATGTGAC 921 
-36runx2b 
chr20:44,121,758-
44,122,750 GTGAAGGCTCCGCTCACCT GGCAAAGACATACCAGGCAAA 993 
+11runx2b 
chr20:44,075,029-
44,075,935 GCGGGGCATGTCAGATTCTA CGACAGAGAGGTGAGCGTGA 907 
+28runx2b 
chr20:44,058,608-
44,059,525 CCAAAACAATGAACGGCAGA CGGCAGCCAGAAGAGAGAAC 918 
+38runx2b 
chr20:44,121,758 -
44,122,750 ACCATCCGACAAGCTGATCC TGGAAATCAATGGGGCAAAA 909 
+52runx2b 
chr20:44,034,157-
44,035,096 TTGAAGCGGGGTTCATTTTG GCCCGAACATGAAGGTAACTC 940 
+54runx2b 
chr20:44,032,209-
44,033,092 TGTGCTCACCTTTAAGTGGTTCA GGGAGAGAGCCCTGAGCATA 884 
+61runx2b 
chr20:44,025,533-
44,026,461 TGGTTCTTAGATGGCAATGAGC CCGTCTCGATTCCTTCAATCC 930 
+66runx2b 
chr20:44,019,065-
44,020,088 GGGAAACATCCATACATAAAAAGTGTT GAAACACACACTCAATCACACTCA 1000 
+84runx2b 
chr20:44,002,595-
44,003,488 TGCTTTAATTTATCATCCTTTTGCAG CCTAACGTGGCGAAAAGGCTA 895 
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CHAPTER 3 
Introduction 
 Having identified three RUNX2 associated enhancers from the human 
genome capable of directing expression to osteoblasts in Chapter 2, I attempted 
to characterize upstream regulators for each CRE. Fortunately, the transgenic 
fish lines I created to describe expression patterns also serve as a useful platform 
to study the underlying biology of their reporter constructs.  
Materials and Methods 
 Site directed mutagenesis. Predicted, conserved transcription factor binding 
sites in +210RUNX2 were identified via linear alignment to its zebrafish 
ortholog, +154runx2a, using Clustal W 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). Binding sites were individually 
mutated via PCR. Briefly, each site was converted into a unique restriction site 
via two parallel PCR reactions with primer pairs that introduced the restriction 
site and attB sequence flanking each ampliconj.  A subsequent digestion and 
ligation step produced a mutagenized enhancer competent for Gateway 
recombination. For -460RUNX2mutTCF and +542RUNX2mutDLX, the mutated 
enhancer sequences were synthesized (GeneWiz), and cloned directly into pattP-
Tol2-egfp as described in Chapter 2. 
 Drug treatments. To screen for responsiveness to candidate signaling 
pathways, embryos transgenic for each enhancer construct were treated from 48 
                                                          
j Mutagenized +210RUNX2 constructs were constructed by Gina Mahatma. 
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to 72 HPF with inhibitors of FGF signaling (SU5402; 10M) BMP signaling 
(dorsomorphin; 30M), retinoic acid (DEAB; 50M), notch (DAPT; 20M), 
hedgehog (cyclopamine; 50M) and calcineurin (FK506; 3M) signaling and 
screened for changes in GFP expression. Additionally, +210RUNX2:egfp embryos 
were treated from 28-32 HPF, or +210RUNX2:mCh embryos from 100-104 HPF, 
with SU5402 at 10 µM, and -460RUNX2:mCh transgenic embryos were treated 
from 52-56 HPF with GSK3 inhibitor XV at 5µM, before being harvested for in 
situ hybridization or Q-PCR analysis. For all treatments, drugs were dissolved in 
DMSO to make stock solutions, which were diluted into embryo medium; 
additional DMSO was added to equalize concentration for all treatments. 
 Heat shock treatments. Embryos doubly transgenic for -460RUNX2:mCh and 
hsp70:dkk1 165  were immersed in pre–warmed embryo medium at 37C for 30 
minutes at 52 HPF. Following heat shock, embryos were transferred to fresh 
embryo medium at 28.5°C and incubated for 3.5 hours before harvesting for 
analysis. For +542RUNX2:egfp, embryos doubly transgenic with either 
hsp70:bmp2b 166  or hsp70:chd 167  were similarly heat shocked at 48 HPF, and 
harvested at 56 HPF. 
 DNA sequence alignments. Orthologs of human sequences were identified by 
BLAT. Sequences were downloaded from the UCSC genome browser, curated 
into FASTA files and aligned using Clustal X (http://www.clustal.org) 
 Confocal imaging, in situ hybridizations, zebrafish transgenesis and 
quantitative RT-PCR all performed as described in Chapter 2. 
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Results – Characterization of +210RUNX2 
 Identification of conserved predicted transcription factor binding sites in 
+210RUNX2 
 The search for sequence features potentially critical for the ability of an 
enhancer to direct skeletal expression was facilitated greatly in the example of 
+210RUNX2. Unlike -460RUNX2 and +542RUNX2, +210RUNX2 is deeply 
conserved, with orthologous sequences alignable from mammals to teleosts (Fig. 
3.1). The site of conserved sequences themselves was similarly preserved; all are 
located in the final intron of either Runx2 or a putatively orthologous gene in 
more poorly annotated genomes.  There are several conserved predicted 
transcription factor binding sites, including two adjacent inverted binding sites 
for Ets-related factors (containing a characteristic 5’-GGA(A/T)-3’ core), a binding 
site for proteins containing a POU DNA binding domain, and one for RUNX2 
itself.  
Functional testing of conserved predicted transcription factor binding sites in 
+210RUNX2 
 In order to test what, if any, function these deeply conserved sequences had 
with regard to the function of the enhancer, these potentially critical residues 
were individually and specifically ablated in new transgenic constructs (Figure 
3.1) Single insert transgenic lines were constructed as in Chapter 2, and these 
were crossed onto fish carrying the wild type +210RUNX2 sequence driving the 
expression of mCherry (+210RUNX2:mCh). Although only representative 
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microscopic photography is demonstrated below, at least three lines of each 
transgene have been constructed to confirm the changes in enhancer activity.  
The +210RUNX2 RUNX2 binding site mediates bone expression. 
 Removal of the RUNX2 binding site produced an enhancer that failed to 
direct expression to bone at any time during the first five days post fertilization. 
(Figure 3.2 a-c). However, this altered enhancer was still capable of directing 
early expression to the branchial arches (Figure 3.2d-f). 
The +210RUNX2 Ets binding sites mediate branchial arch expression. 
  Without the conserved Ets binding sites, +210RUNX2 is still competent to 
direct expression to bony tissues, though this does appear to be less robust 
compared to the activity of the wild type enhancer (Figure 3.3 a-c). Possible 
position integration effects on the autonomy of the transgene currently confound 
confirming this quantitatively. More strikingly, however, this altered enhancer 
failed to direct expression to the branchial arches at 3DPF (Figure 3.3 d-f).  
The +210RUNX2 POU binding site has no confirmable effect on transgene 
activity. 
 Eliminating the POU binding site in +210RUNX2 did not compromise its 
ability to direct expression to the domains of either the branchial arches or 
osteoblasts (Figure 3.4a,d).  eGFP expression driven by +210RUNX2mutPOU did 
appear to be more intense than that typically driven by the wildtype enhancer, 
suggesting that the conserved sequence might actually have a role in 
attenuating expression.  
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+210RUNX2 directed expression is a direct target of FGF signaling.  
 Because of the presence and functionality of two inverted Ets binding sites in 
+210RUNX2, I sought to understand what signaling pathways might be 
mediating gene regulation through those conserved sites. Ets transcription 
factors are often found to be downstream of the FGF signaling pathway 168-170 , 
which, in turn, has a well-appreciated role in skeletogenesis and Runx2 
regulationk. The small molecule inhibitor SU-5402 is a potent and selective 
vascular endothelial growth factor receptor (VEGFR) and fibroblast growth 
factor receptor (FGFR) inhibitor 171 . An initial treatment of 10uM from 24-48 
HPF reduced +210RUNX2:eGFP mediated fluorescence in the branchial arches 
(Fig3.5a,b) To confirm this downregulation was a direct result of modulating 
FGF signaling, I treated +210RUNX2:eGFP transgenic embryos with the Fgf 
inhibitor SU5402 from 28-32 HPF. In situ hybridization showed specific 
reduction of egfp expression in the branchial arches (Fig. 3.5c-f), and Q-PCR 
confirmed a quantitative reduction in transcript levels (Fig. 3.5g). While the ETS 
binding sites are not absolutely required for the later activity of +210RUNX2 in 
differentiated osteoblasts, activity of the enhancer was quantitatively decreased 
by pharmacological inhibition of FGF signaling from 100-104 HPF (Fig. 3.5h), 
demonstrating continued regulation of enhancer activity by the FGF pathway 
during osteoblast differentiation. 
Results – Characterization of +542RUNX2 
                                                          
k Reviewed in Chapter 1 
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 The -460RUNX2 and +542RUNX2 enhancers are less deeply conserved, 
complicating prediction of transcription factor binding sites. To provide evidence 
for specific regulatory inputs, I pharmacologically altered activity of candidate 
signaling pathways in transgenic embryos. Changes in BMP, FGF, retinoic acid, 
notch, hedgehog, calcineurin, and canonical Wnt signaling had no effect on 
+542RUNX2 activity (data not shown).   
A conserved subelement of +542RUNX2 is sufficient to direct osteoblast 
expression. 
 To better localize the essential components of +542RUNX2, I created 
transgenic lines containing the most conserved cores of the element (Figure 3.6a; 
Table3.1) driving eGFP expression. The more conserved of the two (MC1; 
Phastcons LOD = 773) directed expression to osteoblasts in a similar manner to 
the entire element (Figure 3.6b,c). However, bone expression was notably less 
robust than that driven by +542RUNX2. +542RUNX2MC2:eGFP (Phastcons = 
334) expresses in the basihyal and ceratohyal cartilages (Figure 3.6d,e), 
components of the pharyngeal skeleton, but this does not comprise part of the 
expression pattern normally dictated by the intact wild type element. 
A conserved DLX binding site is necessary for +542RUNX2 activity. 
Alignment of the +542RUNX2 enhancer with the orthologous sequence from 
chicken revealed several conserved predicted binding sites (Figure 3.7a). 
Initially, I hypothesized that SATB2 might be directly regulating +542RUNX2 
because of the generalized delay in bone formation observed in Satb2-/- mice 172 .  
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However, ablation of this sequence failed to curtail osteoblast expression 
directed by the enhancer (Figure 3.7b,c). Subsequently, I mutated the core of the 
Dlx binding site and observed no eGFP expression in 500 embryos injected with 
the resulting construct, compared to the readily observable mosaic expression 
regulated by the wild–type sequence (Figure 3.7d,e). Transgenic embryos from 
+542RUNX2mutDLX:eGFP founders showed no eGFP expression, despite 
evidence of germline transmission of the transgene (Figure 3.7h) confirming 
requirement of the Dlx binding site for enhancer activity. 
Results – Characterization of -460RUNX2 
A drug screen identifies GSK-3ß as an inhibitor of -460RUNX2 mediated 
expression. 
Treatment -460RUNX2:egfp fish with a small molecule inhibitor of GSK3 from 
48-72 HPF resulted in a broad upregulation of eGFP expression (Figure 3.8a,b). 
To confirm that this effect is a direct effect of modulating the Wnt pathway, a 
narrower window of treatment from 52-56 HPF (which is relevant to the 
initiation of -460RUNX2 mediated expression in the cleithrum; Figure 2.3) 
demonstrated a similar pattern of upregulation (Figure 3.8c,d). GSK3 is an 
inhibitory component of the canonical Wnt signaling pathway, but can also 
function in other signaling pathways. To confirm Wnt regulation of -460RUNX2, 
we generated embryos doubly transgenic for -460RUNX2:mCh and the Wnt 
inhibitory protein Dkk-1 under control of the hsp70 promoter (hs:Dkk1GFP) 165 . 
A brief heat shock substantially reduced expression of mCherry (Figure 3.8e,f).  
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-460RUNX2 requires two conserved TCF/LEF binding sites to direct 
expression. 
 Canonically, the endpoint of Wnt mediated signaling is the recruitment of 
members of the TCF/LEF family of transcription factors to cognate DNA binding 
sites 173 . There are two predicted TCF/Lef1 binding sites in the -460RUNX2 
sequence, conserved among mammals (Figure 3.9a,b), so I created a transgene in 
which these sites had been mutated (-460RUNX2mutTCF:eGFP). We observed 
no eGFP expression in >500 injected embryos (Figure 3.9d). -
460RUNX2mutTCFLEF:eGFP founders showed no eGFP expression, despite 
evidence of germline transmission of the transgene (Figure 3.9e,f) confirming 
requirement of the TCF/LEF binding sites for enhancer activity.  
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Figure 3.1 -- Deep linear conservation between +210RUNX2 
and other vertebrate orthologs.  Alignment to orthologous sequences from 
other vertebrates reveals conservation of predicted transcription factor binding 
sites, including RUNX2 itself, a binding site for transcription factor containing a 
POU domain and a pair of inverted sites for the Ets family of transcription 
factors. 
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Figure 3.2 – The Runx2 binding site mediates +210RUNX2 directed bone 
expression. (a-c) Lateral views of a doubly transgenic 
+210RUNX2mutRUNX2:eGFP; +210RUNX2:mCh zebrafish show no expression 
in any bony tissue at 5DPF driven by  +210RUNX2mutRUNX2, while this 
activity is intact in +210RUNX2:mCh. (d-f) Ventral views of a doubly transgenic 
+210RUNX2mutRUNX2:eGFP; +210RUNX2:mCh zebrafish show both 
transgenes expressing in the branchial arches at 3 DPF. ba, branchial arches; 
cb5, ceratobranchial 5; cl, cleithrum; op, opercle 
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Figure 3.3 – The ETS binding sites mediates branchial arch expression. 
(a-c) Lateral views of a doubly transgenic +210RUNX2mutETS:eGFP; 
+210RUNX2:mCh zebrafish show attenuated expression in bony tissue at 5DPF 
driven by  +210RUNX2mutETS, while this activity is intact in 
+210RUNX2:mCh. (d-f) Dorsal views of a doubly transgenic 
+210RUNX2mutETS:eGFP; +210RUNX2:mCh zebrafish show failure of 
+210RUNX2mutETS, to express in branchial arches at 3DPF, while this activity 
is intact in +210RUNX2:mCh. ba, branchial arches; cb5, ceratobranchial 5; cl, 
cleithrum; op, opercle 
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Figure 3.4 – The POU binding site is not essential for +210RUNX2 
activity during embryogenesis. (a-c) Lateral views of a doubly transgenic 
+210RUNX2mutPOU:eGFP; +210RUNX2:mCh zebrafish demonstrate 
coexpression in bony tissue at 5DPF by both transgenes. (d-f) Dorsal views of a 
doubly transgenic +210RUNX2mutPOU:eGFP; +210RUNX2:mCh zebrafish 
show coexpression in branchial arches at 3DPF by both transgenes. ba, branchial 
arches; cb5, ceratobranchial 5; cl, cleithrum; op, opercle 
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Figure 3.5 – +210RUNX2 is regulated by the FGF signaling pathway. a,b) 
Treatment of +210RUNX2:egfp transgenics with the FGF inhibitor SU5042 from 
24-48 HPF resulted in loss of transgene expression in the branchial arches. c-f) 
As show shown by in situ hybridization for egfp,  a narrow window of treatment 
from 28-32 HPF this loss of expression is specific and direct. g,h) Q-PCR 
confirmed a quantitative decrease in reporter gene expression following 
treatment for the same interval, and similarly following a later treatment from 
100-104 HPF. Views in a and b are lateral, and in c-f, dorsal, with anterior to the 
left. 
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Figure 3.6 – Subcloning of +542RUNX2 localizes osteoblast activity to a 
433 bp fragment. a) Genome browser view of the original +542RUNX2 element 
with tracks indicating the location of the amplicons for subcloning (black) and 
Phastcon elements upon which those amplicons were designed (brown). b,d) 
Lateral views of 5DPF transgenic embryos carrying +542RUNX2MC1:eGFP (b) 
or (d) +542RUNX2MC2:eGFP. c,e) Ventral views of 5DPF transgenic embryos 
carrying +542RUNX2MC1:eGFP (c) or (e) +542RUNX2MC2:eGFP. ba, branchial 
arches; bh, basihyal; bs, brachiostegal ray; ch, ceratohyal; cl, cleithrum; de, 
dentary; op, opercle; 
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Figure 3.7 – Identification and functional testing of conserved 
transcription factor binding sites in +542RUNX2A) Alignment of 
+542RUNX2 and +312RUNX2(gg) along with transcription factor binding sites 
identified in both by Transfac (blue), Genomatix (orange), or Uniprobe (red) b,c) 
Representative views of eGFP expression pattern in 
+542RUNX2mutSATB2:eGFP at 5DPF. d) Alignment of a predicted SATB2 
binding site to other vertebrate orthologs. Sequence of mutagenized construct is 
shown below. e) Following injection of +542RUNX2:egfp, mosaic expression in 
bones, including the cleithrum of two different embryos (arrows) is readily 
apparent. f) In contrast, >500 embryos injected with +542RUNX2mutDlx:eGFP 
showed no mosaic expression. g) Alignment of a predicted Dlx binding site to 
other vertebrate orthologs. Sequence of mutagenized construct is shown below. 
h) Presence of +542RUNX2mutDLX:eGFP in non-expressing progeny of injected 
founder was confirmed by PCR and sequencing of transgene. cb5; 
ceratobranchial 5; cl, cleithrum; de, dentary; mx, maxilla; op, opercle. 
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Figure 3.8 – -460RUNX2 mediated expression is responsive to Wnt 
mediated signaling. Compared to control (a), activity of -460RUNX2 is 
increased by treatment from 48-72 HPF with GSK3b inhibitor XV. (b) A 
narrower window of treatment (52-56HPF) shows rapid upregulation (d) relative 
to control (c). -460RUNX2 mediated expression (e) is abolished by ectopic 
expression of the Wnt inhibitor dkk1 by heat shock (f). cl, cleithrum; op, opercle 
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Figure 3.9 – -460RUNX2 regulatory competency requires two conserved 
TCF/LEF binding sites. a,b) Alignment of vertebrate genomes to conserved 
TCF/LEF binding sites (a) at chr6:44,835,639-44,835,645(hg19), and b) 
chr6:44,836,005-44,836,012(hg19) in -460RUNX2. Residues that have been 
changed in the mutagenized transgene are indicated below the alignment. c) 
Following injection of -460RUNX2:eGFP, mosaic expression in bone is readily 
apparent at 5 DPF, seen in the cleithra of multiple injected embryos (arrows). d) 
In contrast, following injection of -460RUNX2mutTCFLEF:eGFP, no expression 
was seen in >500 embryos. PCR and sequencing of progeny from injected fish 
confirmed the presence of the transgene with ablated TCF/LEF binding sites (f), 
compared to sequencing of the transgenics with wildtype sequence (e). 
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Name F primer R primer Coordinates (hg18) 
Size 
(bp) 
+542RUNX2 
MC 1 AGACAACACGGGCTCATCGT CCCCAAGGGTCTCTGGATTT 
chr6:45,945,982-
45,946,414 433 
+542RUNX2 
MC 2 CTGGGATGGCCAGAGAGAGG TGGCTTCGATATGCCTCTAGTGTA 
chr6:45,946,358-
45,946,610 253 
 
 
Table 3.1. Sequences of +542RUNX2 tested for enhancer activity. Both 
elements are wholly located within +542RUNX2. The primer sequences are those 
used to amplify the elements from genomic DNA for testing. 
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CHAPTER 4 
Summary of human RUNX2 associated enhancers 
 Runx2 is the common denominator in osteoblast development throughout the 
skeleton, and its levels of expression are critical. As a crucial step in 
understanding the regulation of the gene, and subsequently the skeleton itself, I 
have identified distant osteoblast specific enhancers associated with RUNX2 and 
characterized signaling pathways acting on them. Despite their common feature 
of directing osteoblast expression, they are strikingly diverse. They are widely 
spaced across the locus (Figure 2.1), have no obvious sequence similarity to each 
other, and are conserved across species to varying degrees. While they all direct 
expression to osteoblasts, they do so with differing spatiotemporal dynamics.  
The cleithrum is the first bone to ossify in the zebrafish skeleton and does so 
intramembraneously. Using it as a proxy for the relative timing of expression 
onset yields a sequence of +542RUNX2  +210RUNX2  -460RUNX2 (Figure 
2.3). Whether this is consistent across all bony structures is unclear; it appears 
that the ability to drive expression to the vertebral arches is exclusively a 
property of +542RUNX2 (Figure 2.6).  
 In addition to expression at the resolution of individual bones, 
subpopulations of osteoblasts express the three transgenes differentially. As is 
evidenced by study of opercle development in these transgenic lines (Figure 2.4) 
these enhancers direct expression to different cells within that structure. 
+542RUNX2:eGFP expression is uniform throughout the opercle and cleithrum 
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(Figure 2.3). Combining these observations with its unique expression in the 
vertebral arches and early expression in the cleithrum, it is intriguing to 
speculate that +542RUNX2-mediated expression is the most ‘fundamental’ of the 
three characterized enhancers and tied primarily to osteoblast identity itself.  
The expression pattern directed by +210RUNX2 with respect to the developing 
opercle is similar to that of the fli1:eGFP transgenic line, which labels all neural-
crest derived mesenchyme 161 and may indicate cells that have recently become 
RUNX2+. Finally, -460RUNX2 expression is relatively strongest in the strut and 
the leading edge in the fan structure of the bone. These cells are also sp7:mCh 
positive, indicating their likely active deposition of bone ECM components. The 
opercle fan structure expands via a banding pattern 161 , so -460RUNX2 positive 
cells may be those that have committed to remaining in a specific iteration of 
that process.  
 Finally, these three CREs do not fit the definition of redundant ‘shadow’ 
enhancers 174 that reinforce a response to a single inductive event and ensure 
transcriptional robustness to environmental variability. Rather, they appear to 
integrate inputs from different signaling pathways to induce or maintain Runx2 
expression (Figure 4.1). This observation parallels and complements the 
diversity of signaling inputs capable of accelerating Runx2 expression and 
osteogenic differentiation in the literature. 
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Summary of human RUNX2 associated enhancer activity -- +210RUNX2 directs 
expression to osteoblasts separably through FGF signaling and Runx2 
autoregulation. 
 That +210RUNX2 shares orthology both in sequence and function with an 
element similarly placed in the last intron of the zebrafish Runx2 ortholog 
runx2a (+154runx2a;Figure 2.5) suggests its role in regulating Runx2 activity is 
ancient, and consequential. It also possesses a modularity competent to respond 
to FGF signaling to direct expression to the branchial arches (essentially) or 
osteoblasts (qualitatively), while also possessing a conserved binding site for 
RUNX2 required to direct bone expression. The involvement for FGF signaling 
during osteoblast differentiation generally has been discussed in Chapter 1, so it 
is not surprising that +210RUNX2 directs expression to the calvarial sutures 
that are so sensitive to that signaling axisl.  
 +210RUNX2 also presumably functions as a site for positive autoregulation 
of Runx2 activity. In diverse biological systems, the existence of a positive 
feedback loop is an essential step in the creation of switches with an all-or-none 
‘digital’ output characteristic 175 .  And where better to place a switch incapable of 
nuance than at a gatekeeper gene whose expression above threshold is sufficient 
to completely alter cell fate? Whether the +210Runx2 response to RUNX2 is a 
required step in the commitment of MSCs or chondrocytes to an osteoblastic fate 
is unclear. There may be other unannotated positive and negative feedback loops 
                                                          
l Kague, E. Unpublished observation 
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involving recruitment of RUNX2 to target CREs, to alter cell fate kinetics.  
Analysis of the rat and mouse Runx2 P1 promoters indicated that RUNX2 
binding to the 5’ UTR coding region of Runx2 was capable of suppressing 
transcription in vitro 176 . However, a reasonable hypothesis is that +210RUNX2 
functions to ‘lock in’ a cell to an osteoblastic fate commitment, due to its inability 
to direct bone-specific expression without a conserved binding site. 
Summary of human RUNX2 associated enhancers -- +542RUNX2 directs 
expression to early osteoblasts. 
 Dissection of the activity of +542RUNX2 was focused on the two most 
biologically likely conserved direct upstream regulators. SATB2 is a nuclear 
matrix attachment protein that also functions as a transcription factor. Satb2-/- 
mice have generalized osteoblast differentiation delays as well as craniofacial 
patterning defects. Deletion of the predicted SATB2 binding site from 
+542RUNX2 did not affect the ability of the enhancer to direct expression to 
osteoblasts. Although, SATB2 binds the promoters of and upregulates bone 
marker genes, it is also hypothesized to act as a negative regulator of Hoxa2 
expression during osteoblast differentiation. Whether it might be executing a 
similar role with regards to regulation of +542Runx2 is unclear with respect to 
current experimental evidence.     
 Members of the Dlx family are dynamically expressed during osteoblast 
maturation, suggesting roles in different aspects of this process 177 . During skull 
formation in chick, Dlx5 is expressed in osteoblast progenitors, specifically in 
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response to BMP but not FGF signaling, and its expression activates Runx2 and 
osteogenic differentiation in uncommitted embryonic calvarial mesenchyme 78 . 
Zebrafish dlx5a is expressed in the cleithrum at least as early as the long pec 
stage (~42 HPF) 178 , consistent both with early expression of runx2b and early 
activity of +542RUNX2. Coexpression of bmp2a 178 and bmp2b early in the 
cleithrum is also consistent with a BMP->DLX->RUNX2 signaling axis in these 
cells. However, +542RUNX2 did not demonstrate response to perturbation by 
induction of bmp2b or chd via heat shock (data not shown), confounding the 
impulse to arrive at such a conclusion. While the ablated binding site was 
identified by multiple algorithms as one similar to others capable of recruiting 
DLX proteins, transcription factor binding site profiles are famously degenerate, 
and so it is reasonable that other homeodomain containing proteins could be 
signaling through +542RUNX2. 
Summary of human RUNX2 associated enhancers -460RUNX2 potentially links 
Wnt signaling, Runx2 regulation and variation in common skeletal phenotypes 
and diseases. 
 Although experimental and clinical data indicate that gross aberrations in 
Runx2 expression cause skeletal disorders, smaller individual variations in 
Runx2 dosage might be responsible for differences in variation of non-pathologic 
skeletal phenotypes or susceptibility to disease. A cluster of SNPs associated 
with skeletal conditions (bone mass density (BMD) and osteoarthritis (OA), and 
height in three different populations) by genome wide association studies cluster 
 89 
 
around the Wnt responsive enhancer -460RUNX2 (Figure 4.3; Table4.1) No other 
SNPs associated with skeletal phenotypes are located in the remainder of the 
RUNX2 locus. Wnt signaling has been well implicated in affecting BMD, 
although the precise mechanism of that effect is not clear in the literature. Some 
evidence suggests the effect of Wnt signaling on bone mass is indirect, mediated 
by serotonin secretion by neuroendocrine cells of the gut 179 , although this has 
been disputed 180 . The presented data strongly support a direct role for Wnt 
signaling in osteoblasts, acting via transcriptional regulation of Runx2.  
 The location of -460RUNX2 suggests that variations in the enhancer itself 
alter the risk of low BMD and OA and influence height through changes in 
RUNX2 expression. Interestingly, in addition to its positive association with 
BMD, the canonical Wnt pathway has been implicated in increased 
osteoarthritis risk 181, 182 , as has increased RUNX2 expression 183, 184  Therefore, 
sequence variants in the population may affect either the basal activity of  -
460RUNX2 or its responsiveness to Wnt signaling, accounting for the genetic 
associations with both of these skeletal phenotypes. An intriguing possibility is 
that two alleles at a single location could lead either to increased enhancer 
activity and increased arthritis risk, or decreased enhancer activity and 
increased risk of osteoporosis. 
Runx2 expression modulation as a source of evolutionary skeletal diversity.  
 Runx2 protein activity is positively correlated to facial length in carnivores, 
especially domesticated dogs 185 . This relationship is not generally true among 
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placental mammals, suggesting that other changes, such as in gene expression 
levels, are more likely to correlate with intra– or inter-specific variation 186 . The 
sensitivity of normal skeletal development to precise levels of Runx2 has led to 
the suggestion that alterations in Runx2 activity provide a mechanism for 
skeletal evolution, acting as a ‘tuning knob’ to either accelerate or delay 
osteoblast differentiation during development 186 . Following assembly of the 
Neanderthal genome sequence, the RUNX2 locus was identified as one of the 
regions with the strongest evidence of positive selection in the evolution of 
modern humans 187 . Specifically, the 3' end of RUNX2, encompassing 
+210RUNX2, shows a deficit of derived alleles in modern humans (Figure 4.3a). 
No fixed differences in the RUNX2 coding sequence are present between 
Neanderthal and modern humans, suggesting that the positive selection has 
acted on changes in regulatory sequences. Comparing the human +210RUNX2 
sequence to other primates identifies three derived, human specific SNPs that 
could potentially link this element to the evolution of the human skeleton 
(Figure 4.3b).  Interestingly, many of the differences between the skeletons of 
Neanderthal and modern humans—clavicular morphology, frontal bossing of the 
skull—are similar to the differences observed in cleidocranial dysplasia, which is 
caused by a Runx2 gene dosage defect 127, 188, 189 .   
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Future directions 
Future investigation of the functional consequences of specific sequence 
alterations in the RUNX2 enhancers will shed light on the role of its regulation 
in development, evolution, and disease. An obvious question resulting from the 
screen in Chapter 2 is the thoroughness of it. While it is likely impossible to ever 
know the cis regulatory architecture of single gene in a complex eukaryotic 
genome has been exhaustively annotated, some potential experiments in other 
model systems present themselves to address this question. However, this will 
require divesting ourselves of the zebrafish model. While it has been shown to be 
an effective system for evaluating the regulatory potential of discrete elements in 
the human genome, the existence of two runx2 genes as well as the current size 
limitations of BAC-mediated transgenesis make the fish a poor choice to study 
the intact human Runx2 locus. To try to get a broader locus-wide view of Runx2 
enhancer dynamics during development, we must turn turn to a system with a 
more similar Runx2 structure, namely the mouse. 
 Although not discussed in this document, it is not difficult to obtain a 
population of cells uniformly positive for the Runx2 transgene from early 
embryos. This process necessitates enzymatic digestion followed by flow-
cytometry sorting to derive an enriched population of transgene expressing 
osteoblasts at a relatively discrete stage of development. Sorting based on 
multiple colors/transgenes can further refine this staging. Creating one or more 
mouse transgenic lines using either the +542RUNX2 or -460RUNX2 elements 
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would, assuming expression patterns are similar in the mouse, permit 
exploration for bone specific enhancers in early osteoblasts. This could be done 
by looking for enrichment for histone modifications associated with regulatory 
sequences, or for regions directly associated with RUNX2 itself. Circular 
chromosome conformation capture (4C) allows to us to ask questions specifically 
about the dynamics of the Runx2 locus itself. Using one or both Runx2 promoters 
as ‘bait’, comparing the physical interaction of distal elements with the Runx2 
TSS would presumably yield a list of currently unknown cis regulators, as well 
as informing how they and the currently known Runx2 enhancers function 
dynamically through osteoblast development189.    
 Additionally, as the number of and knowledge regarding individual RUNX2 
cis regulators grows, the genetic tools they offer might be applicable to studying 
bone biology in other contexts than embryonic differentiation. +210RUNX2 
transgenic fish have already been used in a to study bone regeneration post-
amputation 190  as well as suture development in the skull vaultm. Certainly, how 
bones heal post-fracture is a robust area of research 191 , and the ability to 
visualize Runx2 expression during in vivo assays would presumably augment 
them. Finally, the transgenic lines could be incorporate in a high throughput 
screen against a pharmaceutical library 192 , enhancing drug discovery for Runx2 
expression mediators that may aid in therapies for common skeletal disorders 
such as OA and osteoporosis.  
                                                          
m E. Kague, unpublished 
 93 
 
Conclusion 
 Taken together, the data presented in this document provide evidence for 
direct regulation of Runx2 transcription by biologically important signaling 
pathways and transcription factors through three independent enhancers. This 
complex regulatory landscape has allowed the fine–tuning of expression of this 
critical developmental gene through alterations in enhancer activities. 
Furthermore, I hypothesize that these alterations have been selected for in 
evolution, and help account for differences in skeletal morphology among species. 
This data also supports the model that variations in a distal enhancer of RUNX2 
account for genetic associations in the region with height, BMD, and increased 
OA risk.  
   
 
 
 
 
 
 
 
 
 
 94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 95 
 
 
 
 
 
Figure 4.1 -- Model for integration of multiple signaling inputs at the 
Runx2 locus. Three identified enhancers at the Runx2 locus are regulated by 
different upstream factors, and each is capable of interacting independently with 
the transcriptional start site (dotted lines) to activate gene transcription. Once 
transcription is activated via one or more external signals, it is stabilized by 
Runx2 auto-regulation through the intronic enhancer. Downstream, expression 
of Runx2 in mesenchymal precursor cells of diverse embryologic origins leads to 
activation of genes necessary for development of osteoblasts. 
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Figure 4.2 – SNPs associated with skeletal phenotypes and disorders 
cluster near the Wnt responsive enhancer -460RUNX2. A genome browser 
view of the human RUNX2 locus interrogated for regulatory activity shows the 
location of all SNPs associated with a human phenotype by genome wide 
association studies. SNPs associated with skeletal phenotypes are listed in Table 
4.1; rs1932040 is associated with attention deficit hyperactivity disorder. 
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Figure 4.3 – Recent positive selection in the human lineage near 
+210RUNX2. (a) Genome browser view of the human RUNX2 locus. Signals of 
positive selection based on scoring of individual SNPs. A negative score indicates 
more derived alleles in modern humans relative to Neanderthals and is evidence 
of positive selection. SNP scan data obtained from  187 .  (b) Three derived SNPs 
(indicated by red rectangles) in +210RUNX2 are candidate alleles for a recent 
selective sweep in the human lineage. All three are derived with respect to the 
ancestral primate state and have not been observed to be polymorphic in human 
populations. 
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SNP Phenotype MAF Dist from -460RUNX2 (kb) 
rs556621 Atherosclerotic Stroke 0.3 -241 
rs11755164  Bone mass density 0.4 -196 
rs10948172 Osteoarthritis 0.29 58 
rs9472414 Adult Height (European)  0.22 111 
rs10948197 Adult Height (Korean) 0.34 132 
rs9395066 Adult Height (DECODE) 0.48 260 
 
 
 
Table 4.1 – SNPs associated with human skeletal phenotypes in the human 
RUNX2 locus.  Minor allele frequency is given in the studied population. Distance 
from the Wnt responsive enhancer -460RUNX2 is given in kilobases. A negative 
distance indicates distance 5’ to the element, while a positive one denotes 3’ 
separation. 
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